Submission Details
| 510(k) Number | K212512 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | August 10, 2021 |
| Decision Date | April 28, 2022 |
| Days to Decision | 261 days |
| Submission Type | Traditional |
| Review Panel | Orthopedic (OR) |
| Summary | Summary PDF |
K212512 is an FDA 510(k) clearance for the G7? Vivacit-E? Freedom? Constrained Liner, a Prosthesis, Hip, Constrained, Cemented Or Uncemented, Metal/polymer, + Additive (Class II — Special Controls, product code PBI), submitted by Zimmer, Inc. (Warsaw, US). The FDA issued a Cleared decision on April 28, 2022, 261 days after receiving the submission on August 10, 2021. This device falls under the Orthopedic review panel. Regulated under 21 CFR 888.3310.
| 510(k) Number | K212512 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | August 10, 2021 |
| Decision Date | April 28, 2022 |
| Days to Decision | 261 days |
| Submission Type | Traditional |
| Review Panel | Orthopedic (OR) |
| Summary | Summary PDF |
| Product Code | PBI — Prosthesis, Hip, Constrained, Cemented Or Uncemented, Metal/polymer, + Additive |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 888.3310 |
| Definition | For Use As A Component Of A Total Hip Prosthesis In Primary And Revision Patients At High Risk Of Dislocation Due To A History Of Prior Dislocation, Bone Loss, Joint Or Soft Tissue Laxity, Neuromuscular Disease, Or Intraoperative Instability, And For Whom All Other Options To Constrained Acetabular Components Have Been Considered. |